SIGLEC1 and breast cancer: Using RNA sequencing data from the large SCAN-B breast cancer cohort, we showed that SIGLEC1 (CD169) expression in primary breast tumors clustered with the expression of functional TLS signatures, indicating that CD169+ TAMs actually do associate with mature tertiary lymphoid follicles also in primary tumors.